Antibody maker Vaccinex files $46M IPO touting I/O combo drug; Replimune shoots for $100M-plus in IPO
→ After spending over a decade building out a pipeline of antibody drugs to treat cancer, neurological and autoimmune diseases, Vaccinex is riding on this year’s IPO wave and seeking a $46 million raise.
With the infusion, the Rochester, NY-based biotech is looking to fund VX15, its SEMA4D antibody being tested for Huntington’s disease (a Phase II program granted fast track and orphan designation), non-small cell lung cancer as well as melanoma and osteosarcoma. There’s also debt to repay and preclinical research to continue.
For NSCLC, Vaccinex has a pact in place with Merck to test their drug in a combo with the PD-1 inhibitor that the German pharma is co-developing with Pfizer, avelumab, in patients who’ve never been treated with immunotherapy. Look for Vaccinex on Nasdaq under the ticker $VCNX.
→ Replimune is looking to raise more than $100 million from its IPO. The biotech has laid out plans to sell 6.7 million shares at $14 to $16 apiece, leaving them with a market cap of about $500 million. Insiders have a line on $40 million worth of the stock.
→ A UK biotech startup called Synthace has taken up office space at the former BBC office in White City Palace. The company is developing software designed to facilitate development and commercialization. They have 40 staffers now with plans to expand that to 80.